Flare Therapeutics raises $85M in Series C financing led by Third Rock Ventures and Nextech Invest to advance its ARON degrader program.
Amount Raised
$85 Million
Round Type
Series C
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
Flare Therapeutics closed an $85 million Series C financing led by existing investors, including Third Rock Ventures and Nextech Invest. The funding will be used to advance its FX-111 program and for general corporate purposes. Additionally, Anna Protopapas has been appointed as CEO to lead the company through its next growth phase focused on prostate cancer. The financing also includes participation from notable investors such as Pfizer Ventures and Novartis.
Quick answer
Flare Therapeutics raised $85 Million in a Series C round, dated June 30, 2026. Investors: Boxer Capital, Pfizer Ventures, Invus, Novartis, Casdin Capital, Agent Capital, Eventide Asset Management and GordonMD Global Investments® LP. Flare Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Flare Therapeutics raise?
- Flare Therapeutics raised $85 Million in a Series C round on June 30, 2026.
- Who invested in Flare Therapeutics?
- Boxer Capital, Pfizer Ventures, Invus, Novartis, Casdin Capital, Agent Capital, Eventide Asset Management and GordonMD Global Investments® LP are named as investors in this round.
- What does Flare Therapeutics do?
- Flare Therapeutics is a biotechnology company exclusively focused on drugging transcription factors (TFs) to fully unlock the therapeutic potential of this previously elusive target class.
- Where is Flare Therapeutics based and how big is it?
- Flare Therapeutics is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Flare Therapeutics?
- Fundz holds 1 contact at Flare Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Flare Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Apollomics raised $10M on August 14, 2026.
- bioAffinity Technologies raised $4M (Post-IPO Equity) on August 14, 2026.
- Khartis Therapeutics raised $50M (Series B) on August 13, 2026.
- Amplifica Holdings Group raised $26M (Series B) on August 12, 2026.
- InduPro raised $77M (Series B) on August 12, 2026.
- Vaderis Therapeutics raised $152M (Series B) on August 11, 2026.
Who to call at Flare Therapeutics, and when
A new round usually means Flare Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Flare Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Flare Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Flare Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Flare Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Flare Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.